JPWO2022014639A1 - - Google Patents
Info
- Publication number
- JPWO2022014639A1 JPWO2022014639A1 JP2022536419A JP2022536419A JPWO2022014639A1 JP WO2022014639 A1 JPWO2022014639 A1 JP WO2022014639A1 JP 2022536419 A JP2022536419 A JP 2022536419A JP 2022536419 A JP2022536419 A JP 2022536419A JP WO2022014639 A1 JPWO2022014639 A1 JP WO2022014639A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020121525 | 2020-07-15 | ||
| JP2020121525 | 2020-07-15 | ||
| PCT/JP2021/026461 WO2022014639A1 (ja) | 2020-07-15 | 2021-07-14 | Ｅｇｆｒ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022014639A1 true JPWO2022014639A1 (https=) | 2022-01-20 |
| JPWO2022014639A5 JPWO2022014639A5 (https=) | 2023-03-27 |
| JP7495983B2 JP7495983B2 (ja) | 2024-06-05 |
Family
ID=79554696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536419A Active JP7495983B2 (ja) | 2020-07-15 | 2021-07-14 | Ｅｇｆｒ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230285397A1 (https=) |
| EP (1) | EP4197538A4 (https=) |
| JP (1) | JP7495983B2 (https=) |
| KR (1) | KR102873219B1 (https=) |
| CN (1) | CN116368136B (https=) |
| AU (1) | AU2021309779B2 (https=) |
| BR (1) | BR112023000770A2 (https=) |
| CA (1) | CA3189460A1 (https=) |
| MX (1) | MX2023000693A (https=) |
| PH (1) | PH12023550119A1 (https=) |
| TW (1) | TW202216152A (https=) |
| WO (1) | WO2022014639A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492208B2 (en) * | 2020-07-15 | 2025-12-09 | Taiho Pharmaceutical Co., Ltd. | Crystal of pyrimidine compound |
| EP4183395A4 (en) * | 2020-07-15 | 2024-07-24 | Taiho Pharmaceutical Co., Ltd. | PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT |
| JP2024520461A (ja) * | 2021-05-24 | 2024-05-24 | 大鵬薬品工業株式会社 | Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065898A2 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
| WO2013118817A1 (ja) * | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| WO2017038838A1 (ja) * | 2015-09-01 | 2017-03-09 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 |
| WO2020145374A1 (ja) * | 2019-01-11 | 2020-07-16 | 大鵬薬品工業株式会社 | ピリミジン化合物又はその塩 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034885B2 (en) * | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| CA3015484C (en) * | 2016-02-23 | 2022-11-08 | Taiho Pharmaceutical Co., Ltd. | Novel condensed pyrimidine compound or salt thereof |
-
2021
- 2021-07-14 US US18/016,103 patent/US20230285397A1/en active Pending
- 2021-07-14 JP JP2022536419A patent/JP7495983B2/ja active Active
- 2021-07-14 TW TW110125853A patent/TW202216152A/zh unknown
- 2021-07-14 KR KR1020237001973A patent/KR102873219B1/ko active Active
- 2021-07-14 PH PH1/2023/550119A patent/PH12023550119A1/en unknown
- 2021-07-14 CN CN202180061165.8A patent/CN116368136B/zh active Active
- 2021-07-14 CA CA3189460A patent/CA3189460A1/en active Pending
- 2021-07-14 EP EP21842292.1A patent/EP4197538A4/en not_active Withdrawn
- 2021-07-14 AU AU2021309779A patent/AU2021309779B2/en active Active
- 2021-07-14 MX MX2023000693A patent/MX2023000693A/es unknown
- 2021-07-14 WO PCT/JP2021/026461 patent/WO2022014639A1/ja not_active Ceased
- 2021-07-14 BR BR112023000770A patent/BR112023000770A2/pt unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065898A2 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
| WO2013118817A1 (ja) * | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| WO2017038838A1 (ja) * | 2015-09-01 | 2017-03-09 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 |
| WO2020145374A1 (ja) * | 2019-01-11 | 2020-07-16 | 大鵬薬品工業株式会社 | ピリミジン化合物又はその塩 |
| JP6783974B1 (ja) * | 2019-01-11 | 2020-11-11 | 大鵬薬品工業株式会社 | ピリミジン化合物又はその塩 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230285397A1 (en) | 2023-09-14 |
| KR102873219B1 (ko) | 2025-10-17 |
| JP7495983B2 (ja) | 2024-06-05 |
| BR112023000770A2 (pt) | 2023-02-07 |
| EP4197538A1 (en) | 2023-06-21 |
| AU2021309779A1 (en) | 2023-02-23 |
| PH12023550119A1 (en) | 2024-06-24 |
| CN116368136B (zh) | 2025-09-05 |
| CA3189460A1 (en) | 2022-01-20 |
| MX2023000693A (es) | 2023-02-13 |
| AU2021309779B2 (en) | 2024-06-27 |
| WO2022014639A1 (ja) | 2022-01-20 |
| CN116368136A (zh) | 2023-06-30 |
| TW202216152A (zh) | 2022-05-01 |
| EP4197538A4 (en) | 2024-08-07 |
| KR20230026451A (ko) | 2023-02-24 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240524 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7495983 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |